The pharmaceutical firm is joining forces with China International Capital Corporation, the investment bank with which it launched a $1bn fund in 2019.
US-headquartered pharmaceutical firm AstraZeneca launched a RMB2.2bn ($338m) healthcare investment fund with investment banking firm China International Capital Corporation’s private equity vehicle, CICC Capital, yesterday, DealStreetAsia reported.
Wuxi AstraZeneca CICC Investment was officially registered in January this year and is targeting developers of innovative therapeutics, medical devices, diagnostics technology and artificial intelligence-equipped healthcare technology.
In addition to technology, the fund will back the development of innovative supply chain solutions for pharmaceutical companies.
AstraZeneca had previously partnered China International Capital Corporation…
